What is a stock summary page? Click here for an overview.
Business Description
Toleranzia AB
ISIN : SE0007438577
Compare
Compare
Traded in other countries / regions
TOL.Sweden0EH.Germany IPO Date
2015-12-16Description
Toleranzia AB is a Swedish biotechnology Company. The company develops drugs that harness the power of the immune system to treat autoimmune orphan diseases The company's drug candidate, TOL2, is being developed for the treatment of the autoimmune neuromuscular disease myasthenia gravis, an orphan disease.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.97 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 0.6 | |||||
3-Year EPS without NRI Growth Rate | -1.7 | |||||
3-Year FCF Growth Rate | -0.3 | |||||
3-Year Book Growth Rate | -16.9 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 52.18 | |||||
9-Day RSI | 50.47 | |||||
14-Day RSI | 48.61 | |||||
3-1 Month Momentum % | -48.35 | |||||
6-1 Month Momentum % | -27.12 | |||||
12-1 Month Momentum % | -29.94 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.42 | |||||
Quick Ratio | 2.42 | |||||
Cash Ratio | 2.15 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -34.9 | |||||
Shareholder Yield % | -33.83 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -6.01 | |||||
ROA % | -5.71 | |||||
ROIC % | -6.53 | |||||
3-Year ROIIC % | -1.37 | |||||
ROC (Joel Greenblatt) % | -4478.2 | |||||
ROCE % | -5.82 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 0.62 | |||||
Price-to-Tangible-Book | 13.63 | |||||
EV-to-EBIT | -10.11 | |||||
EV-to-Forward-EBIT | 0.99 | |||||
EV-to-EBITDA | -10.17 | |||||
EV-to-Forward-Revenue | 0.47 | |||||
EV-to-FCF | -5.17 | |||||
Price-to-Net-Current-Asset-Value | 13.63 | |||||
Price-to-Net-Cash | 13.63 | |||||
Earnings Yield (Greenblatt) % | -9.9 | |||||
FCF Yield % | -16 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Toleranzia AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil kr) | |||
EPS (TTM) (kr) | -0.044 | ||
Beta | - | ||
3-Year Sharpe Ratio | -0.34 | ||
3-Year Sortino Ratio | -0.46 | ||
Volatility % | 63.12 | ||
14-Day RSI | 48.61 | ||
14-Day ATR (kr) | 0.028941 | ||
20-Day SMA (kr) | 0.4099 | ||
12-1 Month Momentum % | -29.94 | ||
52-Week Range (kr) | 0.27 - 0.748 | ||
Shares Outstanding (Mil) | 270.96 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Toleranzia AB Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Toleranzia AB Stock Events
Event | Date | Price (kr) | ||
---|---|---|---|---|
No Event Data |
Toleranzia AB Frequently Asked Questions
What is Toleranzia AB(OSTO:TOL)'s stock price today?
The current price of OSTO:TOL is kr0.41. The 52 week high of OSTO:TOL is kr0.75 and 52 week low is kr0.27.
When is next earnings date of Toleranzia AB(OSTO:TOL)?
The next earnings date of Toleranzia AB(OSTO:TOL) is 2025-05-06.
Does Toleranzia AB(OSTO:TOL) pay dividends? If so, how much?
Toleranzia AB(OSTO:TOL) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |